Teva was sued by GlaxoSmithKline and Pfizer’s ViiV Healthcare for
infringing a U.S. patent for the HIV drug Epzicom, Bloomberg reported
Monday.

The companies noted that Teva’s submission for approval of a
generic version of Epzicom “constitutes infringement” and “ViiV will be
irreparably harmed” if it’s sold before the patent expires in 2016.

The lawsuit seeks a permanent injunction to block Teva’s US sales of the drug and damages if the generic product is sold.